fda compounding glp-1 warning letters september 2025 to Restrict Ingredients Used in Mass-Marketed Compounded GLP-1s, Crack Down on Misleading Ads From Crackdown to Collaboration: FDA

Burning or pain that lasts well beyond that, or swelling that grows over hours, can mean the shot went too deep (IM instead of SubQ) or a reaction to the preservative reasons to check technique and talk to your provider

Our governance model includes: Prescribing restricted to Dr Nirusha Kumaran and Dr Tasnim Elghandy, both holding valid certification in peptide therapy Quarterly clinical audit of outcomes, adverse events, and adherence Documented discontinuation criteria for every active protocol An active adverse event registry and clinical KPI tracking No prescribing in cases of active malignancy, pregnancy, or severe psychiatric illness This level of institutional rigour is what separates physician-led peptide therapy from the commercially driven, under-regulated alternatives that exist elsewhere in the market

For step-by-step guidance on specific compound classes, the complete peptide research guide covers protocol context that pairs with the reconstitution methodology below